---
schema_version: "secwatch.filing_event.v1"
accession: "0001640334-24-001796"
form_type: "8-K"
ticker: "BDPT"
cik: "0001575142"
company_name: "BIOADAPTIVES, INC."
filed_at: "2024-11-27T23:59:59+00:00"
generated_at: "2026-05-29T14:09:11.603380+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# BioAdaptives gets IRB approval for human trial of weight management product Zeranovia

## Summary
- IRB approved human clinical trial for Zeranovia, a weight management supplement.
- First phase to confirm dosing and identify side effects; participant slots quickly filled.
- CEO notes less than 1% of nutraceuticals undergo human trials; aims for scientific proof.
- Trial managed by doctors in Las Vegas, NV; next stage open to more participants.
- If successful, Zeranovia could compare favorably to synthetic GLP-1 and GIP treatments.

## SEC filing metadata
- accession: 0001640334-24-001796
- form_type: 8-K
- ticker: BDPT
- cik: 0001575142
- company_name: BIOADAPTIVES, INC.
- filed_at: 2024-11-27T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1575142/000164033424001796/0001640334-24-001796-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1575142/000164033424001796/bdpt_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001640334-24-001796
- JSON: https://secwatch.observer/filing/0001640334-24-001796.json
- Plain text: https://secwatch.observer/filing/0001640334-24-001796.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.